AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

FORMA Therapeutics Announces Upcoming Presentations at the 31st Annual Piper Jaffray Healthcare Conference and the 2019 ASH Annual Meeting

December 3, 2019

WATERTOWN, Mass.--(BUSINESS WIRE)--Dec 3, 2019--

FORMA Therapeutics Inc., a clinical stage biopharmaceutical company focused on rare hematologic diseases and cancers, today announced that the company will present at two meetings in December:

About FORMA
FORMA Therapeutics is focused on the discovery, development and commercialization of transformative medicines for patients with rare hematologic diseases and cancers. A fully-integrated biopharmaceutical company, FORMA’s validated, proprietary R&D engine combines deep biology insight, chemistry expertise and clinical development capabilities to create differentiated drug candidates with best-in-class or first-in-class potential. FORMA has delivered high-value clinical candidates to its partners and generated a broad proprietary portfolio of programs, ranging from preclinical to pivotal-stage, with the potential to provide profound patient benefit. For more information, please visit the company website at www.formatherapeutics.com or follow us on Twitter @FORMAInc and LinkedIn.

View source version on businesswire.com:https://www.businesswire.com/news/home/20191203005156/en/

CONTACT: Investor Contact:

Stephanie Ascher, +1 212-362-1200

Stern Investor Relations

stephanie.ascher@sternir.com

Media Contact:

Kari Watson, +1 781-235-3060

MacDougall

kwatson@macbiocom.com

KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS NEW YORK FLORIDA

INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL HEALTH ONCOLOGY

SOURCE: FORMA Therapeutics

Copyright Business Wire 2019.

PUB: 12/03/2019 08:05 AM/DISC: 12/03/2019 08:05 AM

http://www.businesswire.com/news/home/20191203005156/en